Coronado Biosciences Announces Independent Data Monitoring Committee Recommends Discontinuing Falk Phase 2 Trial of TSO in Crohn's Disease

By: Benzinga
Coronado Biosciences (NASDAQ: CNDO ) today announced that it has been informed by Dr. Falk Pharma GmbH (Falk), its development partner, that an Independent Data Monitoring Committee (IDMC) has conducted a second interim analysis of clinical data from approximately 240 patients who have completed 12 weeks of treatment in
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.